Abbott Laboratories (ABT) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pac...
Abbott Laboratories (ABT) currently trades at a P/E ratio of 33.46 (historical range: 12.74–42.50, median: 30.83), placing it at the 69th percentile — above its historical average, P/S ratio of 3.90 (range: 3.20–5.99, 10th percentile — cheap relative to its history), EV/EBITDA of 28.40 (range: 17.77–37.31, 46th percentile).
Over the historical period (2021-09-13 to 2026-10-16), Abbott Laboratories's P/E ratio has contracted by 11% over the observed period (from an average of 29.9 to 26.4).
Abbott Laboratories trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 33.46 | 30.83 | 69th | above its historical average |
| P/S Ratio | 3.90 | 4.67 | 10th | cheap relative to its history |
| EV/EBITDA | 28.40 | 28.84 | 46th | near its historical average |
| FCF Yield | 4.31% | 3.31% | 75th | below its historical average |
Abbott Laboratories (ABT) Valuation & P/E History
Abbott Laboratories (ABT) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry currently trading at $104.13 with a market capitalization of $180.2 billion. This page provides historical valuation analysis for ABT based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 33.46 is above the historical median of 30.83, placing ABT at the 69th percentile of its valuation range. The P/S ratio of 3.90 compares to a median of 4.67.
ABT Valuation Metrics & Historical Range
The valuation table above shows Abbott Laboratories's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ABT is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ABT is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Abbott Laboratories.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ABT Overvalued or Undervalued?
Abbott Laboratories trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 42 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ABT is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ABT analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ABT trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.